Last reviewed · How we verify
Eraxis (anidulafungin)
Anidulafungin inhibits fungal cell wall synthesis by blocking the enzyme glucan synthase, leading to fungal cell death.
Anidulafungin inhibits fungal cell wall synthesis by blocking the enzyme glucan synthase, leading to fungal cell death. Used for Candidemia and other Candida infections (intra-abdominal candidiasis, peritonitis, esophageal candidiasis), Aspergillus fumigatus infections.
At a glance
| Generic name | Eraxis (anidulafungin) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Echinocandin antifungal |
| Target | 1,3-beta-D-glucan synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Anidulafungin is an echinocandin antifungal that selectively inhibits 1,3-beta-D-glucan synthase, a key enzyme in fungal cell wall biosynthesis. By preventing glucan polymerization, it disrupts the structural integrity of the fungal cell wall, causing cell lysis and death. This mechanism is fungicidal against Candida species and has activity against Aspergillus.
Approved indications
- Candidemia and other Candida infections (intra-abdominal candidiasis, peritonitis, esophageal candidiasis)
- Aspergillus fumigatus infections
Common side effects
- Elevated liver enzymes (ALT/AST)
- Hypokalemia
- Infusion-related reactions
- Diarrhea
- Rash
Key clinical trials
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (PHASE3)
- Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.
- A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
- Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
- Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients
- Azole-echinocandin Combination Therapy for Invasive Aspergillosis (PHASE3)
- Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (PHASE2)
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eraxis (anidulafungin) CI brief — competitive landscape report
- Eraxis (anidulafungin) updates RSS · CI watch RSS
- Pfizer portfolio CI